<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623921</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-08-WAA-026911-TLV</org_study_id>
    <nct_id>NCT01623921</nct_id>
  </id_info>
  <brief_title>Statins and Selective Cyclooxygenase-2 Receptor Inhibitors in Blunt Chest Trauma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <brief_summary>
    <textblock>
      Background: Lung contusion affects 17%-25% of adult blunt trauma patients, and is the leading
      cause of death from blunt thoracic injury. Statins are lipid-lowering drugs with recently
      suggested anti-inflammatory and antioxidant properties. Cyclo-oxygenase-2 (COX-2) is a key
      enzyme in the production of prostaglandins (PG), and evidence suggests that COX-2 plays an
      important role in the pathogenesis of acute lung injury (ALI).

      Aims: The current study aims at evaluating the beneficial effects of statins and COX-2
      receptor inhibitors on ALI elicited by blunt trauma to the chest.

      Methods: After approval by the institutional ethics and a scientific committee, and obtaining
      informed consent , patients admitted to the emergency department (ED) due to blunt trauma
      with a diagnosis of lung contusion will be enrolled in the study.The effects of statins and
      COX 2 inhibitors on ALI will be assessed by recording clinical parameters and measuring
      inflammatory mediators levels in the serum and in the bronchoalveolar space.

      Expected results: The investigators expect to find that the proposed treatment will be
      effective in reducing ALI burden. The investigators also suppose that using a combination of
      those drugs will synergistically potentiate their effect on ALI.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Signs of ALI, i.e., pneumonia, adult respiratory distress syndrome [ARDS]</measure>
    <time_frame>3 days</time_frame>
    <description>1. Signs of ALI, i.e., pneumonia, adult respiratory distress syndrome [ARDS] according to following criteria:
Suspected or proven infection
Hypoxemia: PaO2/FiO2is ≤300 mm HgBilateral infiltrates consistent with pulmonary edema
Positive-pressure mechanical ventilation through an endotracheal tube
No clinical evidence of left atrial hypertension to explain bilateral infiltrates
Presence of at least three of the four SIRS criteria. If only two criteria are evidenced, one must be temperature or WBC</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Blunt Chest Trauma</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 4: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard care treatment</intervention_name>
    <description>Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)</description>
    <arm_group_label>Celecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)</description>
    <arm_group_label>rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined therapy</intervention_name>
    <description>Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)</description>
    <arm_group_label>Combined therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years of age

          -  Diagnosis of lung contusion by physical examination, chest xrays, history by the
             patient, accompanying persons or police.

          -  Ability to understand and accept the trial procedures and to sign an informed consent
             form in accordance with national legislation.

          -  Admission to ward

        Exclusion Criteria:

          -  Penetrating trauma

          -  Current use of lipid-lowering therapy, use of non steroidal anti-inflammatory drugs.

          -  Current use of postmenopausal hormone-replacement therapy

          -  Evidence of hepatic dysfunction (an alanine aminotransferase level more than twice the
             upper limit of the normal range), a creatine kinase level more than three times the
             upper limit of the normal range.

          -  Creatinine level higher than 2.0 mg/dl

          -  Known uncontrolled hypertension (systolic blood pressure &gt;190 mm Hg or diastolic blood
             pressure &gt;100 mm Hg

          -  History of uncontrolled hypothyroidism (thyroid-stimulating hormone level&gt; 1.5 times
             the upper limit of the normal range)

          -  Psychiatric disorders

          -  Pregnancy

          -  Known allergy or intolerance to one of the protocol drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Avi A Weinbroum, MD</last_name>
    <phone>3-6973237</phone>
    <phone_ext>972</phone_ext>
    <email>draviw@tasmc.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Avi A Weinbroum, MD</last_name>
      <phone>3-6973237</phone>
      <phone_ext>972</phone_ext>
      <email>draviw@tasmc.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>Michal Roll PhD,MBA</investigator_full_name>
    <investigator_title>Director, Division of Research &amp; Development</investigator_title>
  </responsible_party>
  <keyword>Lung</keyword>
  <keyword>Contusion</keyword>
  <keyword>Injury</keyword>
  <keyword>Cyclooxygenase</keyword>
  <keyword>Statin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Thoracic Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

